|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Diaz-Padilla I, Monk BJ, Mackay HJ and
Oaknin A: Treatment of metastatic cervical cancer: Future
directions involving targeted agents. Crit Rev Oncol Hematol.
85:303–314. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lukka H and Johnston M: Concurrent
cisplatin-based chemotherapy plus radiotherapy for cervical cancer:
A meta-analysis. Clin Oncol (R Coll Radiol). 16:160–161. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pfaendler KS and Tewari KS: Changing
paradigms in the systemic treatment of advanced cervical cancer. Am
J Obstet Gynecol. 214:22–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bayraktar R and Van Roosbroeck K: miR-155
in cancer drug resistance and as target for miRNA-based
therapeutics. Cancer Metastasis Rev. 37:33–44. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang YA, Hu P, Chan KCC and You ZH: Graph
convolution for predicting associations between miRNA and drug
resistance. Bioinformatics:. (pii): btz6212019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tung SL, Huang WC, Hsu FC, Yang ZP, Jang
TH, Chang JW, Chuang CM, Lai CR and Wang LH: miRNA-34c-5p inhibits
amphiregulin-induced ovarian cancer stemness and drug resistance
via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis.
6:e3262017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Z, Wang J, Li J, Wang X and Song W:
MicroRNA-150 promotes cell proliferation, migration and invasion of
cervical cancer through targeting PDCD4. Biomed Pharmacother.
97:511–517. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R,
Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, et al: miR-506 acts as a
tumor suppressor by directly targeting the hedgehog pathway
transcription factor Gli3 in human cervical cancer. Oncogene.
34:717–725. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu R, Zeng G, Gao J, Ren Y, Zhang Z, Zhang
Q, Zhao J, Tao H and Li D: miR-138 suppresses the proliferation of
oral squamous cell carcinoma cells by targeting Yes-associated
protein 1. Oncol Rep. 34:2171–2178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye XW, Yu H, Jin YK, Jing XT, Xu M, Wan ZF
and Zhang XY: miR-138 inhibits proliferation by targeting
3-phosphoinositide-dependent protein kinase-1 in non-small cell
lung cancer cells. Clin Respir J. 9:27–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stojcheva N, Schechtmann G, Sass S, Roth
P, Florea AM, Stefanski A, Stühler K, Wolter M, Müller NS, Theis
FJ, et al: MicroRNA-138 promotes acquired alkylator resistance in
glioblastoma by targeting the Bcl-2-interacting mediator BIM.
Oncotarget. 7:12937–12950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nie W, Huang W, Zhang W, Xu J, Song W,
Wang Y, Zhu A, Luo J, Huang G, Wang Y and Guan X: TXNIP interaction
with the Her-1/2 pathway contributes to overall survival in breast
cancer. Oncotarget. 6:3003–3012. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao Y, Fan X, Li W, Ping W, Deng Y and Fu
X: miR-138-5p reverses gefitinib resistance in non-small cell lung
cancer cells via negatively regulating G protein-coupled receptor
124. Biochem Biophys Res Commun. 446:179–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z,
Liu R, Tang A, Li X, Liu F and Shen S: The tumor suppressor
miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget.
7:45370–45384. 2016.PubMed/NCBI
|
|
19
|
Zhu D, Gu L, Li Z, Jin W, Lu Q and Ren T:
MiR-138-5p suppresses lung adenocarcinoma cell
epithelial-mesenchymal transition, proliferation and metastasis by
targeting ZEB2. Pathol Res Pract. 215:861–872. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu C, Wang M, Chen M, Huang Y and Jiang J:
Upregulation of microRNA1385p inhibits pancreatic cancer cell
migration and increases chemotherapy sensitivity. Mol Med Rep.
12:5135–5140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sossey-Alaoui K and Plow EF:
miR-138-mediated regulation of KINDLIN-2 expression modulates
sensitivity to chemotherapeutics. Mol Cancer Res. 14:228–238. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang X, Jiang J, Zhu J, He N and Tan J:
HOXA4-regulated miR-138 suppresses proliferation and gefitinib
resistance in non-small cell lung cancer. Mol Genet Genomics.
294:85–93. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rastgoo N, Pourabdollah M, Abdi J, Reece D
and Chang H: Dysregulation of EZH2/miR-138 axis contributes to drug
resistance in multiple myeloma by downregulating RBPMS. Leukemia.
32:2471–2482. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yun EJ, Zhou J, Lin CJ, Xu S, Santoyo J,
Hernandez E, Lai CH, Lin H, He D and Hsieh JT: The network of
DAB2IP-miR-138 in regulating drug resistance of renal cell
carcinoma associated with stem-like phenotypes. Oncotarget.
8:66975–66986. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu Z, Tang J, Wang J, Duan G, Zhou L and
Zhou X: MiR-138 acts as a tumor suppressor by targeting EZH2 and
enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS
One. 11:e1500262016.
|
|
26
|
Chen KG and Sikic BI: Molecular pathways:
Regulation and therapeutic implications of multidrug resistance.
Clin Cancer Res. 18:1863–1869. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang B, Wang D, Yan T and Yuan H:
MiR-138-5p promotes TNF-α-induced apoptosis in human intervertebral
disc degeneration by targeting SIRT1 through PTEN/PI3K/Akt
signaling. Exp Cell Res. 345:199–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang R, Liu M, Liang H, Guo S, Guo X, Yuan
M, Lian H, Yan X, Zhang S, Chen X, et al: miR-138-5p contributes to
cell proliferation and invasion by targeting Survivin in bladder
cancer cells. Mol Cancer. 15:822016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu Y, Yang K, Sun X, Fang P, Shi H, Xu J,
Xie M and Li M: MiR-138 suppresses airway smooth muscle cell
proliferation through the PI3K/AKT signaling pathway by targeting
PDK1. Exp Lung Res. 41:363–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Wang Q, Wen R, Liang J, Zhong X,
Yang W, Su D and Tang J: MiR-138 inhibits cell proliferation and
reverses epithelial-mesenchymal transition in non-small cell lung
cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med.
19:2793–2805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siddiqui MS, Francois M, Fenech MF and
Leifert WR: Persistent γH2AX: A promising molecular marker of DNA
damage and aging. Mutat Res Rev Mutat Res. 766:1–19. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Turinetto V and Giachino C: Multiple
facets of histone variant H2AX: A DNA double-strand-break marker
with several biological functions. Nucleic Acids Res. 43:2489–2498.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Seo J, Kim K, Chang DY, Kang HB, Shin EC,
Kwon J and Choi JK: Genome-wide reorganization of histone H2AX
toward particular fragile sites on cell activation. Nucleic Acids
Res. 42:1016–1025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiao H, Tong R, Ding C, Lv Z, Du C, Peng
C, Cheng S, Xie H, Zhou L, Wu J and Zheng S: γ-H2AX promotes
hepatocellular carcinoma angiogenesis via EGFR/HIF-1α-/VEGF
pathways under hypoxic condition. Oncotarget. 6:2180–2192. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bassing CH, Chua KF, Sekiguchi J, Suh H,
Whitlow SR, Fleming JC, Monroe BC, Ciccone DN, Yan C, Vlasakova K,
et al: Increased ionizing radiation sensitivity and genomic
instability in the absence of histone H2AX. Proc Natl Acad Sci USA.
99:8173–8178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Banáth JP, Macphail SH and Olive PL:
Radiation sensitivity, H2AX phosphorylation and kinetics of repair
of DNA strand breaks in irradiated cervical cancer cell lines.
Cancer Res. 64:7144–7149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Huang JW, Li M, Cavenee WK,
Mitchell PS, Zhou X, Tewari M, Furnari FB and Taniguchi T:
MicroRNA-138 modulates DNA damage response by repressing histone
H2AX expression. Mol Cancer Res. 9:1100–1111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang H, Luo J, Liu Z, Zhou R and Luo H:
MicroRNA-138 regulates DNA damage response in small cell lung
cancer cells by directly targeting H2AX. Cancer Invest. 33:126–136.
2015. View Article : Google Scholar : PubMed/NCBI
|
